Skip to contentT
Thermo Fisher Scientific Inc.
T
TMOThermo Fisher Scientific Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$10.89B$10.89Bderived−4.9% vs Q4 2022 Net Income$1.65B$1.65Bderived+4.6% vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Thermo Fisher Scientific Inc. · CIK 97745 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$1,854,000,000−0.4% Operating Cash Flowderived$3,723,000,000+6.8% Free Cash Flowderived$3,318,000,000+13.0% Margins · derivedOperating margin17.0%+0.8 pt vs Q4 2022
Net margin15.1%+1.4 pt vs Q4 2022
ended Dec 31, 2023 · filed Feb 22, 2024 · 53 d after period end